In this article, we will explore 10 penny stocks with potential to rise 1000 percent.
Penny stocks can produce eye-catching bursts of upside, but their record against the broader market is usually weaker once you zoom out. Using BlackRock ETF proxies for comparison, the iShares Micro-Cap ETF returned 22.8% in 2025, ahead of the iShares Core S&P 500 ETF’s 17.9%, but over 10 years, the micro-cap fund annualized 9.4% versus 14.8% for the S&P 500 proxy. Risk was also much higher: the micro-cap fund’s three-year standard deviation was 22.5%, versus 12.0% for the S&P 500 fund. The SEC also notes that penny stocks tend to be less liquid, more volatile, and easier to manipulate, while academic work on lottery-like stocks has generally found lower future returns despite their appeal to speculators.
A large share of penny-stock growth stories tends to cluster in biotech and AI for structural reasons. In BlackRock’s micro-cap proxy, health care was the largest sector at 30.4%, while information technology accounted for 15.1%. Biotech fits the penny-stock mold because many firms are pre-revenue, cash-burning, and valued mainly on clinical milestones rather than current earnings. AI attracts similar speculative flows from the other direction: investors are trying to price in a rapidly expanding market, with Gartner projecting global AI spending of $2.52 trillion in 2026, up 44% year over year. In both cases, small companies can move sharply because expectations shift faster than fundamentals.
Source: Freepik
Methodology
We used consensus sentiment from Wall Street analysts and financial media websites to compile our list of penny stocks with the potential to rise 1000 percent over the next few years. We then limited our final selection to companies that have recently reported noteworthy developments likely to affect investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the penny stocks with the potential to rise 1000 percent.
On March 27, Rocket Pharmaceuticals said the FDA approved KRESLADI for a rare pediatric disorder, giving the company its first marketed product and a key regulatory win after a long review path. The company said the approval also makes KRESLADI the first FDA-approved gene therapy for this condition, which gives Rocket a commercial foothold in an ultra-rare disease market.
The bigger takeaway is what came with the approval. Rocket said it also received a Rare Pediatric Disease Priority Review Voucher, an asset biotech companies can monetize, and management said it is evaluating strategic options for the voucher to enhance financial flexibility. The company added that it plans to make KRESLADI available to eligible U.S. patients.
Rocket has also been signaling a measured launch rather than a broad commercial push. Recent company disclosures described a scaled commercial effort tailored to the very small patient population, while Reuters reported the rollout is expected to begin through a limited number of specialized centers. As of December 31, 2025, Rocket had $188.9 million in cash, cash equivalents, and investments.
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on genetic therapies for rare disorders. Its pipeline includes lentiviral and AAV-based programs targeting immunologic and cardiovascular diseases.
9. Datavault AI Inc. (NASDAQ:DVLT)
Datavault AI Inc. (NASDAQ:DVLT) is one of the penny stocks with the potential to rise 1000 percent.
On March 19, 2026, Datavault AI reported its first profitable quarter and record revenue growth for fiscal 2025. The company said fourth-quarter revenue reached $33.8 million, up 3,650% year over year, while operating profit improved to $4.2 million from a $6.3 million loss a year earlier. It also reported a net profit of $661 thousand for the quarter, which it described as the first in its history. For the full-year 2025, revenue rose 1,362% to $39.1 million, while gross profit reached $30 million, with a gross margin of about 78%.
The company also pointed to a stronger balance sheet at year-end, with about $116 million in working capital, $142.9 million in current assets, $26.9 million in current liabilities, and no long-term debt. On outlook, Datavault AI reiterated its full-year 2026 revenue target of $200 million, which it said would represent nearly 400% year-over-year growth from fiscal 2025. That target is management guidance and, as the company noted, remains subject to forward-looking risks and uncertainties.
Datavault AI Inc. develops AI-driven data monetization, credentialing, digital engagement, and tokenization technologies through its Acoustic Sciences and Data Sciences divisions. The company is headquartered in Philadelphia.
8. Vertical Aerospace (NYSE:EVTL)
Vertical Aerospace (NYSE:EVTL) is one of the penny stocks with the potential to rise 1000 percent.
On March 27, Vertical Aerospace said it selected Italy-based Isoclima S.p.A. as a strategic supplier for the full transparency suite on its Valo aircraft, including pilot and passenger canopies and glazing systems. The company said the long-term partnership is intended to support the program through certification, production, and entry into commercial service, while adding Isoclima to a supplier roster that already includes Honeywell, Aciturri, Evolito, and Syensqo.
Vertical said aircraft transparencies must meet requirements including bird-strike resistance, structural loads, and environmental stress while maintaining visibility standards. It said the agreement is intended to provide supply stability and technical continuity as development of Valo advances.
In a March 24 update, Vertical said transition testing for Valo is underway and that it is now focused on certification and scaling production. The company also said it expects approximately $195 million of net cash outflows over the next 12 months as it increases investment in flight testing, certification, and manufacturing. In a separate March 18 release, Vertical said its battery pilot production line had become operational.
Vertical Aerospace is a global aerospace and technology company pioneering electric aviation. Valo is a piloted, four-passenger eVTOL aircraft, and the company says it has about 1,500 pre-orders across four continents.
7. Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Jasper Therapeutics Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent.
UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upside. The note also said investors likely want to see longer-term durability data, with limited near-term catalysts, before topline data from the BEACON Phase 2b study in chronic spontaneous urticaria, or CSU, expected in 2027.
The call came after Jasper had already reported updated data for briquilimab on January 8. The company said 67% of additional patients treated with briquilimab in the BEACON Phase 1b/2a study achieved a complete response at 12 weeks, while 83% achieved a complete response by week 3 after the initial dose. Jasper also said the BEACON and open-label extension data were enough to support dose selection for a Phase 2b study in CSU planned to begin in the second half of 2026.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company developing briquilimab, an antibody therapy targeting KIT (CD117), for mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
6. Gossamer Bio, Inc. (NASDAQ:GOSS)
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the penny stocks with the potential to rise 1000 percent.
Gossamer Bio remained in focus in March 2026 after its late-February Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension missed its primary endpoint, though the company said it planned to meet with the U.S. Food and Drug Administration to discuss a potential path forward and paused enrollment in the SERANATA study while it reviewed the data.
Even after cutting their price targets, both Oppenheimer and H.C. Wainwright kept bullish ratings on the stock. On March 5, Oppenheimer maintained its Outperform rating and lowered its target to $3 from $12. On March 6, H.C. Wainwright maintained its Buy rating and cut its target to $5 from $10. Based on Gossamer Bio’s recent share price of about $0.37, Oppenheimer’s target still implied upside of more than 700%, while H.C. Wainwright’s target implied upside of more than 1,200%.
Public summaries of the H.C. Wainwright update noted that analyst Patrick Trucchio reduced the estimated probability of success for seralutinib in PAH to 50% from 70%. Even so, later reporting on the firm’s view said the data still “demonstrate evidence of clinical activity,” particularly in heavily pretreated patients, and that “a path forward may yet emerge,” although regulatory and capital uncertainty would likely remain an overhang.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for pulmonary hypertension and other serious diseases.
5. Rezolve AI PLC (NASDAQ:RZLV)
Rezolve AI PLC (NASDAQ:RZLV) is one of the penny stocks with potential to rise 1000 percent.
Rezolve AI said on February 10 that it had agreed to acquire Reward Loyalty UK Limited in an all-cash deal valued at $230 million, with the purchase funded from existing resources. The company described the transaction as non-dilutive, meaning it does not require the issuance of new equity, and said the acquisition is expected to add about $90 million of EBITDA-accretive revenue.
The deal gives Rezolve a profitable commerce media, engagement, and loyalty platform that already operates across banking and retail channels. In its announcement, the company said Reward has live enterprise deployments spanning banks, retailers, and payment ecosystems, which Rezolve expects will broaden the reach of its RezolvePay and Brain Commerce offerings across tens of millions of cardholders and a large merchant network.
Rezolve framed the acquisition as a scale move rather than a distant bet. The company said Reward’s platform has delivered more than $2.5 billion in cashback to consumers, generated more than $1 billion in gross merchandise value in 2025, and worked with banks including NatWest, Monzo, Mashreq, and Zand.
Rezolve AI PLC is an AI-driven commerce and payments infrastructure company focused on digital retail tools, including Brain Commerce for product discovery and Brain Checkout for one-tap checkout.
4. agilon health, inc. (NYSE:AGL)
agilon health inc. (NYSE:AGL) is one of the penny stocks with potential to rise 1000 percent.
agilon health said on March 18, 2026, that it would implement a 1-for-25 reverse stock split of its common stock as it works to regain compliance with the New York Stock Exchange’s minimum bid price requirement. The company said the reverse split is expected to become effective on March 30, 2026, at around 5:01 p.m. Eastern Time, with shares expected to begin trading on a split-adjusted basis on March 31 under the existing ticker symbol AGL.
The company said stockholders had approved an amendment at a March 17 special meeting authorizing a reverse split in a range of 1-for-5 to 1-for-25, with the board given discretion to determine the final ratio. Following that meeting, the board approved the 1-for-25 ratio. agilon said the move is intended not only to lift its share price above $1.00 for continued NYSE listing compliance, but also to potentially improve the marketability and liquidity of the stock and broaden investor interest.
Under the reverse split, every 25 outstanding shares will be combined into one share, leaving about 16.6 million shares outstanding immediately after the effective time. The company said no fractional shares will be issued, with stockholders instead receiving cash in lieu of any fractional interests. It also said equity awards and other outstanding equity-linked securities would be adjusted proportionally.
agilon health, inc. (NYSE:AGL) partners with physician groups and health systems to support a value-based care model for senior patients, providing technology, capital, and operational support across its network.
3. Aardvark Therapeutics, Inc. (NASDAQ:AARD)
Aardvark Therapeutics Inc. (NASDAQ:AARD) is one of the penny stocks with potential to rise 1000 percent.
Aardvark Therapeutics said on March 23, 2026, that it had voluntarily paused its Phase 3 HERO and open-label extension trials of ARD-101 in Prader-Willi syndrome, as well as the ARD-201 obesity program, while it works with the FDA on next steps. The company said it expects to provide further guidance on both programs in the second quarter of 2026.
The update was driven by cardiac findings from a separate healthy volunteer study, not from prior Prader-Willi syndrome trials. Aardvark said two of eight participants in a healthy volunteer cohort dosed at 1,600 mg twice daily without prior dose escalation had QRS increases greater than 25% from baseline, while another had an increase below that threshold. In a follow-on healthy volunteer cohort dosed at 800 mg twice daily for up to one week, one of 23 participants had a transient QRS increase of less than 25% from baseline, and another had an increase greater than 25%. The company said these observations were reversible, were not reported as serious adverse events, and were not accompanied by serious cardiac symptoms.
Aardvark said preliminary analysis showed a clear exposure-response relationship, with higher plasma concentrations associated with a higher risk of QRS prolongation. It added that ARD-101 data were published in Molecular Metabolism in March. The company ended 2025 with $110.0 million in cash, cash equivalents, and short-term investments, which it said should fund operations into the second quarter of 2027.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies designed to suppress hunger in Prader-Willi syndrome and metabolic diseases.
2. Allogene therapeutics (NASDAQ:ALLO)
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the penny stocks with potential to rise 1000 percent.
Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in the pivotal Phase 2 ALPHA3 trial in first-line consolidation for large B-cell lymphoma. The company said the study is the first designed to test whether early, measurable residual disease-guided consolidation with cema-cel can prevent recurrence in LBCL, and that it is enrolling across more than 60 activated clinical trial sites in academic and community cancer centers, including sites outside the United States. An interim futility analysis is planned for April 2026 and will compare MRD clearance rates and early safety outcomes between the cema-cel arm and observation.
The company also highlighted progress in autoimmune disease with ALLO-329, a dual CD19/CD70 AlloCAR T candidate that uses its Dagger technology to reduce or potentially eliminate conventional lymphodepletion. Allogene said the Phase 1 RESOLUTION basket trial is enrolling in dose escalation across indications, including systemic lupus erythematosus, lupus nephritis, scleroderma, and inflammatory myositis, with initial data from the first dosing cohort expected in June 2026.
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company developing off-the-shelf allogeneic CAR T cell products for cancer and autoimmune disease.
1. Humacyte Inc. (NASDAQ:HUMA)
Humacyte, Inc. (NASDAQ:HUMA) is one of the penny stocks with potential to rise 1000 percent.
On March 27, 2026, BTIG maintained its Buy rating on Humacyte but cut its price target to $3 from $6 after the company reported fourth-quarter and full-year 2025 results earlier the same day. Humacyte reported $0.5 million in fourth-quarter revenue and $2.0 million in full-year revenue, while BTIG said the quarterly figure missed its $1.3 million estimate. The analyst note also said the company posted a loss per share of $0.13, versus consensus expectations for a $0.12 loss.
BTIG said the trauma launch for Symvess remains choppy on a quarter-to-quarter basis. The firm noted that Humacyte sold about 25 units in the fourth quarter, down from about 29 in the third quarter of 2025, while the price per unit declined to roughly $17,000 from about $24,500. BTIG also flagged elevated operating expenses and said cash remains a critical focus.
Even so, BTIG pointed to some commercial progress, with the number of hospitals ordering Symvess for trauma use rising to 27 from 16. Humacyte also said on March 27 that it received a purchase commitment for a minimum of $1.475 million for a clinical evaluation and outreach program in Saudi Arabia, while both the company and BTIG highlighted interim top-line results from the Phase 3 V012 study in dialysis access expected in the second quarter of 2026. BTIG said the dialysis access market represents a larger opportunity than the trauma market.
Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Hedge Fund Resource Center